Dec. 4 at 5:24 AM
$SENS One cannot help but imagine what Senseonics might achieve under a truly proactive and strategically minded leadership team. We are dealing with a technology that has the potential to improve, if not save, lives — yet market adoption remains inexplicably stagnant.
Any capable CEO in this sector would be vigorously engaging with policymakers, regulators, and industry stakeholders — including the current US administration and the FDA — to secure enhanced visibility, support, and potentially even preferential consideration for a product that is demonstrably superior in accuracy and longevity.
Unfortunately, this level of strategic leadership remains absent. The contrast between what could be achieved and what is being delivered under Mr Goodnow is nothing short of staggering.
As shareholders, it is increasingly difficult to comprehend the complacency at the very top when the company’s underlying technology remains one of the strongest assets in the entire CGM space.
